Literature DB >> 9693400

The effects of progesterone and progestins on endometrial proliferation.

D L Moyer1, J C Felix.   

Abstract

A total of 99 premenopausal and 27 postmenopausal women were evaluated to determine the quantity of glandular proliferation resulting from progestin inhibition of estrogen-primed subjects and of subjects without hormonal stimulation. Endometrial glandular proliferation rates were determined by using mitosis counts, proliferating-cell nuclear antigen (PCNA), and nuclear cyclin (MIB1) immunocytological staining. The endometria of normally cycling premenopausal women, of women who received a synthetic progestin, and of untreated postmenopausal women were studied. In untreated normally cycling premenopausal women, the proliferation of the glandular epithelium was increased during the follicular phase and decreased during the luteal phase. Premenopausal women receiving a synthetic progestin and untreated postmenopausal women who were not estrogen-primed showed minimal epithelial proliferation. Endometrial glandular proliferation is inhibited by endogenous progesterone in premenopausal women. Endometrial proliferation is markedly reduced in premenopausal women receiving a synthetic progestin and in untreated postmenopausal women.

Entities:  

Keywords:  Americas; Biology; Clinical Research; Developed Countries; Endocrine System; Endometrial Effects; Endometrium; Estrogens--side effects; Genitalia; Genitalia, Female; Hormone Replacement Therapy; Hormones; Menopause; North America; Northern America; Physiology; Progestational Hormones; Progesterone--beneficial effects; Reproduction; Research Methodology; Research Report; Treatment; United States; Urogenital System; Uterus

Mesh:

Substances:

Year:  1998        PMID: 9693400     DOI: 10.1016/s0010-7824(98)00047-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

Review 2.  Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes.

Authors:  Hyunyoung Jeong
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-06       Impact factor: 4.481

3.  Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin.

Authors:  Steven K Nordeen; Betty J Bona; David N Jones; James R Lambert; Twila A Jackson
Journal:  Horm Cancer       Date:  2013-07-09       Impact factor: 3.869

4.  Optimization of endometrial preparation results in a normal endometrial function test (EFT) and good reproductive outcome in donor ovum recipients.

Authors:  H J Kliman; S Honig; D Walls; M Luna; J C McSweet; Alan B Copperman
Journal:  J Assist Reprod Genet       Date:  2006-09-17       Impact factor: 3.412

Review 5.  Bioidentical hormone therapy.

Authors:  Julia A Files; Marcia G Ko; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-04-29       Impact factor: 7.616

6.  Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer.

Authors:  Lingeng Lu; Harvey Risch; Melinda L Irwin; Susan T Mayne; Brenda Cartmel; Peter Schwartz; Thomas Rutherford; Herbert Yu
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

7.  Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.

Authors:  Gabriela F Meresman; Carla Olivares; Susana Vighi; Margarita Alfie; Marcela Irigoyen; Juan J Etchepareborda
Journal:  Reprod Biol Endocrinol       Date:  2010-10-22       Impact factor: 5.211

Review 8.  Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents.

Authors:  Jeremi M Carswell; Stephanie A Roberts
Journal:  Transgend Health       Date:  2017-11-01

9.  Evaluation of extended and continuous use oral contraceptives.

Authors:  Kristen Page Wright; Julia V Johnson
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.